Investing

Today's Market Winners And Losers (6/21/2012)

While the Dow Jones Industrial Average, S&P 500 and NASDAQ are down slightly today after weak data on the U.S. labor market.  Nevertheless, there are several big winners and losers as of midday. Three of four of today’s featured stocks are in healthcare, two of which are in pharmaceuticals. Here are the midday big winners and losers.


 

Biggest Winners

Shares of Onyx Pharmaceuticals (NASDAQ: ONXX) are up 37.82% to $62.33 based on trading volume of approximately 15 million shares. The company’s cancer drug, carfilzomb, received an 11 to 1 vote from a Food & Drug Administration advisory panel in favor of approval. The FDA is expected to make a final decision by next month.

Shares of Sun Healthcare Group (NASDAQ: SUNH) are up 36.16% to $8.36 on trading volume of nearly 17 million shares. The company announced Wednesday that it would be acquired by privately held Genesis HealthCare for $273.3 million. The merging of the nursing home operators will consist of 400 facilities throughout the U.S.


Biggest Losers

Shares of Bed Bath and Beyond (NASDAQ: BBBY) are down 14.89% to 62.70 based on trading volume of 7.9 million shares. The retailer predicted Wednesday its second-quarters earning would be between 97 cents and $1.03 a share, down from $1.08 that the street was expecting.

Shares of Celgene (NASDAQ: CELG) are down 11.41% to $59.50 based on trading volume of 12 million shares. The company withdrew an application to market its cancer drug, Revlimid, in the European Union. The company said it now plans on seeking approval in 2013 instead of 2012.

Sam Weigley

Find a Qualified Financial Advisor (Sponsor)

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.